Add to Favourites
To login click here
Recursion, a leading clinical stage TechBio company, has signed agreements to acquire two companies in the AI-enabled drug discovery space: Cyclica and Valence. The acquisitions will add industry-leading capabilities in digital chemistry, machine-learning and artificial intelligence, which combined with Recursion’s large-scale automated wet-laboratories and supercomputing capabilities, will enable the company to deploy a complete, technology-enabled drug discovery solution. Cyclica’s MatchMaker™ and POEM™ products will be integrated into the RecursionOS.